 Laurence Levine
Concepts (480)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Penile Induration | 80 | 2019 | 81 | 32.030 |
Why?
| | Penis | 44 | 2019 | 53 | 14.920 |
Why?
| | Erectile Dysfunction | 35 | 2019 | 42 | 10.910 |
Why?
| | Penile Prosthesis | 24 | 2019 | 24 | 8.070 |
Why?
| | Penile Implantation | 12 | 2019 | 12 | 5.630 |
Why?
| | Patient Satisfaction | 25 | 2019 | 257 | 4.900 |
Why?
| | Male | 159 | 2019 | 15601 | 4.620 |
Why?
| | Spermatic Cord | 10 | 2018 | 12 | 4.390 |
Why?
| | Urologic Surgical Procedures, Male | 14 | 2019 | 18 | 4.310 |
Why?
| | Penile Erection | 22 | 2019 | 25 | 4.310 |
Why?
| | Traction | 13 | 2018 | 22 | 4.190 |
Why?
| | Denervation | 9 | 2018 | 20 | 3.960 |
Why?
| | Verapamil | 15 | 2014 | 37 | 3.910 |
Why?
| | Humans | 163 | 2019 | 26729 | 3.540 |
Why?
| | Microbial Collagenase | 8 | 2019 | 10 | 3.500 |
Why?
| | Urethra | 7 | 2019 | 17 | 3.410 |
Why?
| | Testicular Diseases | 7 | 2016 | 10 | 3.170 |
Why?
| | Urethral Stricture | 6 | 2017 | 8 | 3.000 |
Why?
| | Middle Aged | 79 | 2019 | 10097 | 2.780 |
Why?
| | Vasectomy | 4 | 2018 | 5 | 2.750 |
Why?
| | Microsurgery | 9 | 2018 | 43 | 2.750 |
Why?
| | Retrospective Studies | 34 | 2019 | 2780 | 2.720 |
Why?
| | Penile Diseases | 4 | 2017 | 5 | 2.720 |
Why?
| | Adult | 75 | 2019 | 8754 | 2.590 |
Why?
| | Treatment Outcome | 39 | 2019 | 3364 | 2.420 |
Why?
| | Scrotum | 4 | 2017 | 8 | 2.230 |
Why?
| | Mitomycin | 3 | 2017 | 13 | 2.180 |
Why?
| | Injections, Intralesional | 17 | 2018 | 32 | 2.070 |
Why?
| | Priapism | 8 | 2016 | 9 | 2.060 |
Why?
| | Pericardium | 6 | 2019 | 26 | 2.040 |
Why?
| | Chronic Pain | 4 | 2016 | 80 | 2.010 |
Why?
| | Aged | 50 | 2019 | 8906 | 1.970 |
Why?
| | Prostatectomy | 7 | 2019 | 23 | 1.860 |
Why?
| | Algorithms | 8 | 2018 | 385 | 1.830 |
Why?
| | Pain, Postoperative | 5 | 2018 | 223 | 1.830 |
Why?
| | Postoperative Complications | 13 | 2018 | 978 | 1.570 |
Why?
| | Ketoconazole | 3 | 2013 | 6 | 1.530 |
Why?
| | Pelvic Pain | 2 | 2016 | 11 | 1.450 |
Why?
| | Physical Therapy Modalities | 2 | 2016 | 67 | 1.430 |
Why?
| | Urinary Bladder Diseases | 3 | 2015 | 9 | 1.420 |
Why?
| | Intermittent Urethral Catheterization | 2 | 2015 | 2 | 1.390 |
Why?
| | Contracture | 2 | 2015 | 13 | 1.380 |
Why?
| | Vasodilator Agents | 6 | 2011 | 28 | 1.350 |
Why?
| | Calcium Channel Blockers | 5 | 2015 | 37 | 1.320 |
Why?
| | Clostridium histolyticum | 4 | 2019 | 4 | 1.310 |
Why?
| | Postoperative Period | 7 | 2019 | 213 | 1.270 |
Why?
| | Hypogonadism | 4 | 2014 | 4 | 1.260 |
Why?
| | Pelvis | 3 | 2017 | 25 | 1.200 |
Why?
| | Testosterone | 5 | 2013 | 34 | 1.200 |
Why?
| | Pain, Intractable | 3 | 2012 | 16 | 1.180 |
Why?
| | Follow-Up Studies | 18 | 2019 | 1872 | 1.170 |
Why?
| | Young Adult | 12 | 2019 | 1937 | 1.160 |
Why?
| | Phosphodiesterase 5 Inhibitors | 3 | 2018 | 4 | 1.140 |
Why?
| | Phosphodiesterase Inhibitors | 7 | 2011 | 18 | 1.140 |
Why?
| | Collagenases | 7 | 2019 | 23 | 1.130 |
Why?
| | Piperazines | 8 | 2012 | 87 | 1.110 |
Why?
| | Practice Guidelines as Topic | 10 | 2016 | 348 | 1.100 |
Why?
| | Reconstructive Surgical Procedures | 4 | 2016 | 191 | 1.080 |
Why?
| | Suction | 6 | 2012 | 42 | 1.050 |
Why?
| | Patient Compliance | 3 | 2018 | 193 | 1.030 |
Why?
| | Prospective Studies | 14 | 2018 | 1590 | 1.000 |
Why?
| | Urology | 4 | 2014 | 16 | 0.990 |
Why?
| | Adolescent | 15 | 2018 | 2397 | 0.970 |
Why?
| | Pelvic Floor | 2 | 2016 | 8 | 0.950 |
Why?
| | Suburethral Slings | 1 | 2019 | 2 | 0.920 |
Why?
| | Urinary Incontinence, Stress | 1 | 2019 | 4 | 0.910 |
Why?
| | Premature Ejaculation | 1 | 2019 | 2 | 0.900 |
Why?
| | Hemostatics | 1 | 2019 | 9 | 0.900 |
Why?
| | Mouth Mucosa | 3 | 2008 | 13 | 0.900 |
Why?
| | Combined Modality Therapy | 6 | 2018 | 453 | 0.850 |
Why?
| | Psychotherapy | 1 | 2018 | 41 | 0.830 |
Why?
| | Testis | 4 | 2008 | 11 | 0.820 |
Why?
| | Urogenital Surgical Procedures | 1 | 2017 | 1 | 0.820 |
Why?
| | Pain | 5 | 2013 | 278 | 0.800 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2017 | 24 | 0.800 |
Why?
| | Sutures | 1 | 2017 | 41 | 0.780 |
Why?
| | Sexual Behavior | 5 | 2016 | 52 | 0.780 |
Why?
| | Digital Rectal Examination | 1 | 2016 | 4 | 0.770 |
Why?
| | Epididymis | 4 | 2016 | 12 | 0.750 |
Why?
| | Vascular Surgical Procedures | 1 | 2016 | 45 | 0.730 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2016 | 23 | 0.730 |
Why?
| | Spermatozoa | 3 | 2003 | 9 | 0.730 |
Why?
| | Nicardipine | 1 | 2015 | 5 | 0.720 |
Why?
| | Free Radical Scavengers | 1 | 2015 | 12 | 0.720 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 20 | 0.710 |
Why?
| | Oligospermia | 3 | 2003 | 3 | 0.710 |
Why?
| | Recurrence | 7 | 2017 | 354 | 0.710 |
Why?
| | Testicular Hydrocele | 2 | 2012 | 4 | 0.690 |
Why?
| | Ultrasonography, Doppler, Duplex | 6 | 2018 | 17 | 0.690 |
Why?
| | Iontophoresis | 4 | 2011 | 8 | 0.690 |
Why?
| | Anticonvulsants | 1 | 2016 | 100 | 0.690 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 97 | 0.680 |
Why?
| | Impotence, Vasculogenic | 3 | 2010 | 4 | 0.670 |
Why?
| | Ischemia | 3 | 2013 | 27 | 0.670 |
Why?
| | Quality of Life | 4 | 2016 | 534 | 0.660 |
Why?
| | Vacuum | 6 | 2018 | 6 | 0.650 |
Why?
| | Prosthesis Design | 7 | 2018 | 437 | 0.650 |
Why?
| | Radiotherapy | 1 | 2014 | 62 | 0.630 |
Why?
| | 14-alpha Demethylase Inhibitors | 1 | 2013 | 1 | 0.630 |
Why?
| | Sulfones | 8 | 2012 | 25 | 0.610 |
Why?
| | Homosexuality, Male | 1 | 2013 | 17 | 0.600 |
Why?
| | Calcinosis | 1 | 2013 | 47 | 0.600 |
Why?
| | Prosthesis Failure | 2 | 2012 | 476 | 0.590 |
Why?
| | Genital Diseases, Male | 1 | 2012 | 5 | 0.590 |
Why?
| | Sclerotherapy | 1 | 2012 | 2 | 0.580 |
Why?
| | Doxycycline | 1 | 2012 | 23 | 0.580 |
Why?
| | Pain Measurement | 5 | 2016 | 421 | 0.560 |
Why?
| | Nerve Block | 1 | 2012 | 53 | 0.540 |
Why?
| | Cystitis | 4 | 1993 | 10 | 0.530 |
Why?
| | Administration, Oral | 4 | 2015 | 153 | 0.530 |
Why?
| | Ultrasonography | 6 | 2011 | 186 | 0.510 |
Why?
| | Pentoxifylline | 4 | 2011 | 6 | 0.500 |
Why?
| | Equipment and Supplies | 2 | 2008 | 14 | 0.500 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2014 | 510 | 0.500 |
Why?
| | Pain Management | 3 | 2017 | 116 | 0.500 |
Why?
| | Drug Resistance | 1 | 2010 | 62 | 0.490 |
Why?
| | Double-Blind Method | 8 | 2013 | 515 | 0.490 |
Why?
| | Transsexualism | 1 | 2010 | 4 | 0.480 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2012 | 309 | 0.480 |
Why?
| | Ejaculation | 3 | 2019 | 7 | 0.480 |
Why?
| | Attitude of Health Personnel | 2 | 2012 | 166 | 0.470 |
Why?
| | Clomiphene | 1 | 2009 | 1 | 0.470 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2009 | 4 | 0.470 |
Why?
| | Luteinizing Hormone | 1 | 2009 | 7 | 0.470 |
Why?
| | Infertility, Male | 1 | 2009 | 5 | 0.470 |
Why?
| | Follicle Stimulating Hormone | 1 | 2009 | 17 | 0.470 |
Why?
| | Fibrosis | 3 | 2016 | 50 | 0.460 |
Why?
| | Pilot Projects | 5 | 2015 | 389 | 0.460 |
Why?
| | Aged, 80 and over | 10 | 2019 | 4537 | 0.460 |
Why?
| | Sperm Count | 2 | 2001 | 3 | 0.450 |
Why?
| | Hormone Replacement Therapy | 1 | 2009 | 35 | 0.450 |
Why?
| | Prednisone | 1 | 2009 | 72 | 0.450 |
Why?
| | Glucocorticoids | 1 | 2009 | 66 | 0.440 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2008 | 7 | 0.430 |
Why?
| | Autonomic Denervation | 1 | 2008 | 1 | 0.420 |
Why?
| | Carboprost | 3 | 1993 | 3 | 0.420 |
Why?
| | Tromethamine | 3 | 1993 | 4 | 0.420 |
Why?
| | Matrix Metalloproteinases | 1 | 2008 | 31 | 0.420 |
Why?
| | Social Adjustment | 1 | 2008 | 32 | 0.420 |
Why?
| | Cyclophosphamide | 4 | 1993 | 58 | 0.420 |
Why?
| | Self Concept | 1 | 2008 | 48 | 0.420 |
Why?
| | Primary Health Care | 2 | 2007 | 85 | 0.420 |
Why?
| | Interleukin-1beta | 1 | 2008 | 54 | 0.410 |
Why?
| | Lichen Sclerosus et Atrophicus | 1 | 2007 | 1 | 0.410 |
Why?
| | Body Image | 1 | 2008 | 37 | 0.410 |
Why?
| | Referral and Consultation | 3 | 2016 | 88 | 0.400 |
Why?
| | Postoperative Care | 4 | 2012 | 129 | 0.400 |
Why?
| | Trifluoperazine | 1 | 2007 | 4 | 0.400 |
Why?
| | Magnesium Sulfate | 1 | 2007 | 9 | 0.400 |
Why?
| | Wounds, Nonpenetrating | 1 | 2007 | 20 | 0.400 |
Why?
| | Family Practice | 1 | 2007 | 20 | 0.390 |
Why?
| | Wounds and Injuries | 1 | 2007 | 54 | 0.390 |
Why?
| | Expert Testimony | 4 | 2010 | 13 | 0.390 |
Why?
| | Urologic Surgical Procedures | 3 | 2018 | 7 | 0.390 |
Why?
| | Sperm Motility | 1 | 2006 | 2 | 0.390 |
Why?
| | Transforming Growth Factor beta | 1 | 2008 | 134 | 0.380 |
Why?
| | Rupture | 3 | 2014 | 104 | 0.380 |
Why?
| | Evidence-Based Medicine | 6 | 2010 | 215 | 0.360 |
Why?
| | United States | 6 | 2014 | 2104 | 0.360 |
Why?
| | Clinical Competence | 2 | 2012 | 245 | 0.350 |
Why?
| | Prevalence | 3 | 2013 | 496 | 0.340 |
Why?
| | Purines | 8 | 2012 | 30 | 0.340 |
Why?
| | Drug Administration Schedule | 3 | 2014 | 255 | 0.330 |
Why?
| | Gels | 3 | 2015 | 11 | 0.330 |
Why?
| | Drug Combinations | 4 | 2019 | 84 | 0.330 |
Why?
| | Severity of Illness Index | 4 | 2018 | 1145 | 0.330 |
Why?
| | Anemia, Sickle Cell | 2 | 2013 | 11 | 0.310 |
Why?
| | Patient Selection | 2 | 2019 | 235 | 0.310 |
Why?
| | Prosthesis-Related Infections | 2 | 2017 | 179 | 0.300 |
Why?
| | Endoscopy | 2 | 2017 | 164 | 0.300 |
Why?
| | Risk Factors | 5 | 2016 | 2312 | 0.300 |
Why?
| | Tissue and Organ Harvesting | 1 | 2003 | 25 | 0.300 |
Why?
| | Administration, Topical | 3 | 2015 | 23 | 0.300 |
Why?
| | Anesthetics, Local | 2 | 2016 | 82 | 0.300 |
Why?
| | Abdominal Neoplasms | 1 | 2003 | 13 | 0.300 |
Why?
| | Clinical Protocols | 2 | 2013 | 62 | 0.300 |
Why?
| | Antioxidants | 1 | 2003 | 64 | 0.290 |
Why?
| | Esophageal Neoplasms | 1 | 2003 | 58 | 0.280 |
Why?
| | Carcinoma, Renal Cell | 1 | 2003 | 75 | 0.280 |
Why?
| | Patient Education as Topic | 2 | 2018 | 184 | 0.280 |
Why?
| | Time Factors | 5 | 2015 | 1736 | 0.270 |
Why?
| | Animals | 8 | 2017 | 4851 | 0.270 |
Why?
| | Varicocele | 2 | 2001 | 3 | 0.270 |
Why?
| | Skin Transplantation | 3 | 2014 | 21 | 0.270 |
Why?
| | Recovery of Function | 4 | 2018 | 289 | 0.260 |
Why?
| | Colchicine | 3 | 2011 | 7 | 0.260 |
Why?
| | Hemorrhage | 2 | 1992 | 68 | 0.260 |
Why?
| | Interferons | 2 | 2011 | 17 | 0.260 |
Why?
| | Semen | 1 | 2001 | 4 | 0.260 |
Why?
| | Remission Induction | 3 | 2012 | 121 | 0.260 |
Why?
| | Tissue Transplantation | 2 | 2011 | 23 | 0.240 |
Why?
| | Papaverine | 3 | 2011 | 4 | 0.240 |
Why?
| | Carnitine | 2 | 2011 | 6 | 0.240 |
Why?
| | Arginine | 2 | 2011 | 16 | 0.240 |
Why?
| | Catheterization | 2 | 1997 | 61 | 0.230 |
Why?
| | Electric Stimulation Therapy | 2 | 2011 | 44 | 0.230 |
Why?
| | Ultrasonography, Doppler, Color | 2 | 1996 | 9 | 0.230 |
Why?
| | Surgical Sponges | 1 | 2019 | 1 | 0.230 |
Why?
| | Prostatic Neoplasms | 4 | 2014 | 132 | 0.230 |
Why?
| | Thrombin | 1 | 2019 | 14 | 0.230 |
Why?
| | Injections | 3 | 2018 | 58 | 0.220 |
Why?
| | Fibrinogen | 1 | 2019 | 33 | 0.220 |
Why?
| | Consensus | 3 | 2016 | 59 | 0.220 |
Why?
| | Counseling | 1 | 2019 | 62 | 0.220 |
Why?
| | Forecasting | 2 | 2019 | 128 | 0.220 |
Why?
| | Cohort Studies | 3 | 2013 | 1650 | 0.220 |
Why?
| | Urological Agents | 1 | 2018 | 2 | 0.220 |
Why?
| | Orgasm | 1 | 2018 | 8 | 0.220 |
Why?
| | Coitus | 1 | 2018 | 4 | 0.220 |
Why?
| | PubMed | 1 | 2018 | 12 | 0.220 |
Why?
| | Drug Therapy, Combination | 3 | 2011 | 251 | 0.220 |
Why?
| | Child | 5 | 2008 | 1393 | 0.220 |
Why?
| | Device Removal | 1 | 2019 | 97 | 0.210 |
Why?
| | Personal Satisfaction | 1 | 2018 | 43 | 0.210 |
Why?
| | Transplants | 1 | 2017 | 11 | 0.210 |
Why?
| | Allografts | 1 | 2019 | 111 | 0.210 |
Why?
| | Specimen Handling | 1 | 1998 | 49 | 0.200 |
Why?
| | Physical Examination | 2 | 2012 | 108 | 0.200 |
Why?
| | Surgeons | 1 | 2018 | 44 | 0.200 |
Why?
| | Surgical Flaps | 2 | 1998 | 56 | 0.190 |
Why?
| | Reperfusion | 1 | 2016 | 12 | 0.190 |
Why?
| | Age Factors | 3 | 2011 | 829 | 0.190 |
Why?
| | Antibiotic Prophylaxis | 1 | 2017 | 33 | 0.190 |
Why?
| | Anastomosis, Surgical | 3 | 2007 | 55 | 0.190 |
Why?
| | Lung Neoplasms | 1 | 2003 | 717 | 0.190 |
Why?
| | Vasovasostomy | 1 | 2016 | 1 | 0.190 |
Why?
| | Orchiectomy | 1 | 2016 | 5 | 0.190 |
Why?
| | Urethral Diseases | 1 | 1996 | 3 | 0.190 |
Why?
| | Papillomaviridae | 1 | 1996 | 27 | 0.180 |
Why?
| | Oils | 1 | 2015 | 1 | 0.180 |
Why?
| | Self Care | 1 | 1997 | 104 | 0.180 |
Why?
| | Tumor Virus Infections | 1 | 1996 | 18 | 0.180 |
Why?
| | Papillomavirus Infections | 1 | 1996 | 33 | 0.180 |
Why?
| | History, 20th Century | 1 | 2016 | 89 | 0.180 |
Why?
| | Research Design | 2 | 2007 | 188 | 0.170 |
Why?
| | Interferon-alpha | 1 | 1996 | 82 | 0.170 |
Why?
| | Myofibroblasts | 1 | 2015 | 3 | 0.170 |
Why?
| | Transforming Growth Factor alpha | 1 | 2015 | 7 | 0.170 |
Why?
| | Pregnancy | 3 | 2003 | 373 | 0.170 |
Why?
| | Product Surveillance, Postmarketing | 2 | 2008 | 17 | 0.170 |
Why?
| | Prosthesis Implantation | 1 | 2015 | 43 | 0.170 |
Why?
| | Prognosis | 3 | 2012 | 920 | 0.170 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2014 | 27 | 0.170 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 38 | 0.170 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2014 | 28 | 0.170 |
Why?
| | Collagen | 1 | 2015 | 114 | 0.170 |
Why?
| | Disease Management | 1 | 2016 | 123 | 0.170 |
Why?
| | Hematoma | 1 | 2014 | 18 | 0.170 |
Why?
| | Hypopituitarism | 1 | 2014 | 3 | 0.160 |
Why?
| | Medical Records | 1 | 2014 | 40 | 0.160 |
Why?
| | Nitric Oxide | 1 | 2015 | 103 | 0.160 |
Why?
| | Software | 1 | 1994 | 69 | 0.160 |
Why?
| | Reactive Oxygen Species | 1 | 2015 | 124 | 0.160 |
Why?
| | Circumcision, Male | 1 | 2014 | 7 | 0.160 |
Why?
| | Female | 11 | 2013 | 15965 | 0.160 |
Why?
| | Hematuria | 2 | 1993 | 16 | 0.160 |
Why?
| | Amputation, Traumatic | 2 | 2010 | 4 | 0.160 |
Why?
| | Disease Progression | 2 | 2011 | 759 | 0.160 |
Why?
| | Polycystic Kidney Diseases | 1 | 1994 | 4 | 0.160 |
Why?
| | Carotid Artery, Internal | 1 | 2014 | 26 | 0.160 |
Why?
| | Carotid Artery Diseases | 1 | 2014 | 39 | 0.160 |
Why?
| | Leuprolide | 1 | 1993 | 4 | 0.150 |
Why?
| | Monitoring, Physiologic | 2 | 2009 | 90 | 0.150 |
Why?
| | Managed Care Programs | 1 | 2013 | 11 | 0.150 |
Why?
| | Ureter | 1 | 1993 | 25 | 0.150 |
Why?
| | Arteries | 3 | 2002 | 20 | 0.150 |
Why?
| | Splints | 2 | 2004 | 2 | 0.150 |
Why?
| | Constriction | 2 | 2004 | 4 | 0.150 |
Why?
| | Sexuality | 1 | 2013 | 19 | 0.150 |
Why?
| | Chronic Disease | 2 | 2008 | 485 | 0.150 |
Why?
| | Intracranial Aneurysm | 1 | 2014 | 81 | 0.140 |
Why?
| | Mesentery | 1 | 1992 | 6 | 0.140 |
Why?
| | Urinary Tract | 1 | 1992 | 2 | 0.140 |
Why?
| | Connective Tissue | 1 | 2012 | 27 | 0.140 |
Why?
| | Kidney Neoplasms | 1 | 1994 | 106 | 0.140 |
Why?
| | Stents | 1 | 2014 | 146 | 0.140 |
Why?
| | Medical History Taking | 2 | 2003 | 23 | 0.140 |
Why?
| | Ligation | 2 | 2006 | 36 | 0.140 |
Why?
| | Drug Implants | 1 | 2012 | 13 | 0.140 |
Why?
| | Kidney Transplantation | 1 | 1994 | 120 | 0.140 |
Why?
| | Depressive Disorder | 1 | 2014 | 213 | 0.140 |
Why?
| | Circadian Rhythm | 1 | 1995 | 258 | 0.140 |
Why?
| | Reoperation | 2 | 2017 | 798 | 0.140 |
Why?
| | Adenocarcinoma | 1 | 1994 | 227 | 0.130 |
Why?
| | Alprostadil | 1 | 1991 | 11 | 0.130 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 25 | 0.130 |
Why?
| | Linear Models | 1 | 2012 | 257 | 0.130 |
Why?
| | 4-Aminobenzoic Acid | 1 | 2011 | 1 | 0.130 |
Why?
| | Emergency Service, Hospital | 1 | 2013 | 142 | 0.130 |
Why?
| | Body Weights and Measures | 1 | 2011 | 7 | 0.130 |
Why?
| | Placebos | 1 | 2011 | 84 | 0.130 |
Why?
| | Intestines | 1 | 1992 | 102 | 0.130 |
Why?
| | Electroconvulsive Therapy | 1 | 2011 | 17 | 0.130 |
Why?
| | Tamoxifen | 1 | 2011 | 27 | 0.130 |
Why?
| | Vitamin E | 1 | 2011 | 41 | 0.130 |
Why?
| | Organ Size | 1 | 2011 | 116 | 0.130 |
Why?
| | Prostaglandins F, Synthetic | 1 | 1990 | 2 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 87 | 0.120 |
Why?
| | Sexology | 1 | 2010 | 1 | 0.120 |
Why?
| | Wounds, Penetrating | 1 | 2010 | 8 | 0.120 |
Why?
| | Replantation | 1 | 2010 | 7 | 0.120 |
Why?
| | Medicine | 1 | 2010 | 9 | 0.120 |
Why?
| | Transplantation, Autologous | 2 | 2008 | 209 | 0.120 |
Why?
| | Drug Dosage Calculations | 1 | 2009 | 7 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 2 | 2007 | 1124 | 0.120 |
Why?
| | Drug Costs | 1 | 2009 | 16 | 0.120 |
Why?
| | Urination Disorders | 1 | 1989 | 6 | 0.110 |
Why?
| | Health Status Indicators | 1 | 2010 | 83 | 0.110 |
Why?
| | Carcinoma, Transitional Cell | 1 | 1989 | 21 | 0.110 |
Why?
| | Smoking | 1 | 1990 | 170 | 0.110 |
Why?
| | Heart Failure | 1 | 2012 | 188 | 0.110 |
Why?
| | Risk Assessment | 2 | 2012 | 719 | 0.110 |
Why?
| | Urinary Bladder Neoplasms | 1 | 1989 | 43 | 0.110 |
Why?
| | Actinomycosis | 1 | 1988 | 3 | 0.110 |
Why?
| | Retroperitoneal Space | 1 | 1988 | 13 | 0.110 |
Why?
| | Penicillins | 1 | 1988 | 12 | 0.110 |
Why?
| | Darkness | 1 | 2008 | 17 | 0.110 |
Why?
| | Regional Blood Flow | 3 | 1995 | 18 | 0.110 |
Why?
| | Social Isolation | 1 | 2008 | 24 | 0.110 |
Why?
| | Sclerosing Solutions | 1 | 1988 | 3 | 0.110 |
Why?
| | Tetracycline | 1 | 1988 | 5 | 0.110 |
Why?
| | Feedback | 1 | 2008 | 24 | 0.110 |
Why?
| | Interview, Psychological | 1 | 2008 | 45 | 0.110 |
Why?
| | Prostate | 1 | 2008 | 33 | 0.110 |
Why?
| | Graft Survival | 1 | 2008 | 109 | 0.110 |
Why?
| | Focus Groups | 1 | 2008 | 79 | 0.110 |
Why?
| | Abscess | 1 | 1988 | 20 | 0.110 |
Why?
| | Prejudice | 1 | 2008 | 38 | 0.100 |
Why?
| | Urography | 1 | 2007 | 4 | 0.100 |
Why?
| | Trauma Severity Indices | 1 | 2007 | 16 | 0.100 |
Why?
| | Cystoscopy | 1 | 2007 | 4 | 0.100 |
Why?
| | Accidents, Traffic | 1 | 2007 | 26 | 0.100 |
Why?
| | Wisconsin | 1 | 2007 | 5 | 0.100 |
Why?
| | Rectum | 1 | 2007 | 68 | 0.100 |
Why?
| | Interpersonal Relations | 1 | 2008 | 111 | 0.100 |
Why?
| | Suture Techniques | 1 | 2008 | 128 | 0.100 |
Why?
| | Health Care Surveys | 1 | 2007 | 75 | 0.100 |
Why?
| | Epidermal Growth Factor | 1 | 1986 | 34 | 0.090 |
Why?
| | Illinois | 1 | 2007 | 221 | 0.090 |
Why?
| | Heptanoic Acids | 1 | 2006 | 5 | 0.090 |
Why?
| | Pyrroles | 1 | 2006 | 22 | 0.090 |
Why?
| | Anticholesteremic Agents | 1 | 2006 | 25 | 0.090 |
Why?
| | Child, Preschool | 1 | 2008 | 752 | 0.090 |
Why?
| | Peptides | 1 | 1986 | 113 | 0.090 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2005 | 2 | 0.090 |
Why?
| | Therapeutic Irrigation | 2 | 1995 | 58 | 0.080 |
Why?
| | Transplantation, Heterologous | 1 | 2003 | 25 | 0.080 |
Why?
| | Prolactin | 1 | 2003 | 2 | 0.080 |
Why?
| | Pituitary Diseases | 1 | 2003 | 3 | 0.080 |
Why?
| | Fertilization in Vitro | 1 | 2003 | 3 | 0.080 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2003 | 3 | 0.080 |
Why?
| | Pituitary Gland | 1 | 2003 | 14 | 0.080 |
Why?
| | Drug Administration Routes | 1 | 2003 | 9 | 0.080 |
Why?
| | Electricity | 1 | 2003 | 10 | 0.080 |
Why?
| | Steroids | 1 | 2003 | 27 | 0.080 |
Why?
| | Tissue Distribution | 1 | 2003 | 46 | 0.080 |
Why?
| | Fatal Outcome | 1 | 2003 | 71 | 0.070 |
Why?
| | Epinephrine | 1 | 2003 | 30 | 0.070 |
Why?
| | Venous Thrombosis | 1 | 2003 | 46 | 0.070 |
Why?
| | Vascular Diseases | 1 | 2002 | 43 | 0.070 |
Why?
| | Immediate-Early Proteins | 1 | 2002 | 6 | 0.070 |
Why?
| | Cadaver | 1 | 2003 | 331 | 0.070 |
Why?
| | Calcium | 1 | 1986 | 483 | 0.070 |
Why?
| | Repressor Proteins | 1 | 2002 | 52 | 0.070 |
Why?
| | Sex Counseling | 1 | 2000 | 1 | 0.060 |
Why?
| | Hemodynamics | 2 | 2012 | 103 | 0.060 |
Why?
| | Decision Trees | 1 | 2000 | 21 | 0.060 |
Why?
| | Clinical Laboratory Techniques | 1 | 2000 | 20 | 0.060 |
Why?
| | Drug Interactions | 1 | 2000 | 70 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2002 | 319 | 0.060 |
Why?
| | Urination | 1 | 1998 | 4 | 0.050 |
Why?
| | Fascia | 1 | 1998 | 11 | 0.050 |
Why?
| | Reproductive Techniques | 1 | 1998 | 1 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2000 | 370 | 0.050 |
Why?
| | Mucous Membrane | 1 | 1998 | 40 | 0.050 |
Why?
| | Heterografts | 1 | 2017 | 15 | 0.050 |
Why?
| | Urodynamics | 1 | 1997 | 4 | 0.050 |
Why?
| | Global Health | 1 | 2018 | 52 | 0.050 |
Why?
| | Incidence | 1 | 2000 | 727 | 0.050 |
Why?
| | Adipose Tissue | 1 | 1998 | 81 | 0.050 |
Why?
| | Head and Neck Neoplasms | 1 | 1979 | 132 | 0.050 |
Why?
| | Conscious Sedation | 1 | 1997 | 5 | 0.050 |
Why?
| | Anesthesia, Local | 1 | 1997 | 5 | 0.050 |
Why?
| | Internet | 1 | 2018 | 86 | 0.050 |
Why?
| | Societies, Medical | 1 | 2018 | 183 | 0.050 |
Why?
| | Ecchymosis | 1 | 1995 | 2 | 0.040 |
Why?
| | Ephedrine | 1 | 1995 | 4 | 0.040 |
Why?
| | Blood Flow Velocity | 1 | 1995 | 25 | 0.040 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 85 | 0.040 |
Why?
| | Data Interpretation, Statistical | 1 | 1995 | 93 | 0.040 |
Why?
| | Angiography | 1 | 1995 | 46 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 1996 | 296 | 0.040 |
Why?
| | Knowledge Bases | 1 | 2014 | 3 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 1997 | 585 | 0.040 |
Why?
| | Thrombosis | 1 | 1995 | 63 | 0.040 |
Why?
| | Reference Values | 1 | 1994 | 249 | 0.040 |
Why?
| | Cerebral Angiography | 1 | 2014 | 65 | 0.040 |
Why?
| | Australia | 1 | 2013 | 40 | 0.040 |
Why?
| | Endovascular Procedures | 1 | 2014 | 63 | 0.040 |
Why?
| | Administration, Intravesical | 1 | 1993 | 6 | 0.040 |
Why?
| | Ureteral Obstruction | 1 | 1993 | 15 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 373 | 0.040 |
Why?
| | Urologic Diseases | 1 | 1993 | 5 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 1993 | 37 | 0.040 |
Why?
| | Blood Transfusion | 1 | 1993 | 63 | 0.040 |
Why?
| | Methods | 1 | 1992 | 25 | 0.040 |
Why?
| | Edema | 1 | 1992 | 39 | 0.030 |
Why?
| | Coronary Circulation | 1 | 2012 | 43 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2012 | 70 | 0.030 |
Why?
| | Veins | 1 | 1991 | 10 | 0.030 |
Why?
| | Sleep | 1 | 1994 | 273 | 0.030 |
Why?
| | Color | 1 | 1991 | 8 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 1992 | 465 | 0.030 |
Why?
| | Laparoscopy | 1 | 1993 | 172 | 0.030 |
Why?
| | Survival Analysis | 1 | 2012 | 372 | 0.030 |
Why?
| | Drug Evaluation | 1 | 1990 | 57 | 0.030 |
Why?
| | Vasoconstriction | 1 | 1990 | 20 | 0.030 |
Why?
| | Rats | 1 | 1992 | 915 | 0.030 |
Why?
| | Acrolein | 1 | 1989 | 1 | 0.030 |
Why?
| | Clostridium | 1 | 1968 | 2 | 0.030 |
Why?
| | Protease Inhibitors | 1 | 1968 | 21 | 0.030 |
Why?
| | Blood | 1 | 1968 | 27 | 0.030 |
Why?
| | Drainage | 1 | 1988 | 53 | 0.030 |
Why?
| | Radiography | 1 | 1991 | 699 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2012 | 749 | 0.030 |
Why?
| | Area Under Curve | 1 | 2007 | 74 | 0.030 |
Why?
| | Ambulatory Care | 1 | 1988 | 81 | 0.030 |
Why?
| | Prostheses and Implants | 1 | 1989 | 165 | 0.030 |
Why?
| | Prostaglandins E | 1 | 1986 | 5 | 0.020 |
Why?
| | Transforming Growth Factors | 1 | 1986 | 2 | 0.020 |
Why?
| | Dinoprostone | 1 | 1986 | 28 | 0.020 |
Why?
| | Parathyroid Hormone | 1 | 1986 | 23 | 0.020 |
Why?
| | Kinetics | 1 | 1986 | 271 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2006 | 40 | 0.020 |
Why?
| | Mice | 2 | 1986 | 1664 | 0.020 |
Why?
| | Empty Sella Syndrome | 1 | 2003 | 2 | 0.020 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2007 | 262 | 0.020 |
Why?
| | Pituitary Neoplasms | 1 | 2003 | 14 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2007 | 1194 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1988 | 823 | 0.020 |
Why?
| | Adenoma | 1 | 2003 | 42 | 0.020 |
Why?
| | Inhibitor of Differentiation Protein 2 | 1 | 2002 | 1 | 0.020 |
Why?
| | Early Growth Response Protein 1 | 1 | 2002 | 4 | 0.020 |
Why?
| | Pancreatic Elastase | 1 | 2002 | 3 | 0.020 |
Why?
| | Ubiquitin | 1 | 2002 | 34 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2002 | 25 | 0.020 |
Why?
| | Terminology as Topic | 1 | 2001 | 51 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 209 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2002 | 118 | 0.020 |
Why?
| | Down-Regulation | 1 | 2002 | 129 | 0.020 |
Why?
| | Up-Regulation | 1 | 2002 | 198 | 0.020 |
Why?
| | Transcription Factors | 1 | 2002 | 166 | 0.020 |
Why?
| | Gene Expression | 1 | 2002 | 256 | 0.020 |
Why?
| | Comorbidity | 1 | 2002 | 488 | 0.020 |
Why?
| | Palliative Care | 1 | 2001 | 104 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2002 | 229 | 0.010 |
Why?
| | Cytokines | 1 | 2002 | 331 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2002 | 778 | 0.010 |
Why?
| | Eponyms | 1 | 1998 | 2 | 0.010 |
Why?
| | History, 16th Century | 1 | 1998 | 4 | 0.010 |
Why?
| | History, 18th Century | 1 | 1998 | 11 | 0.010 |
Why?
| | Wound Healing | 1 | 1979 | 161 | 0.010 |
Why?
| | Cryptorchidism | 1 | 1993 | 4 | 0.010 |
Why?
| | Prostate-Specific Antigen | 1 | 1993 | 18 | 0.010 |
Why?
| | Lymphatic Metastasis | 1 | 1993 | 99 | 0.010 |
Why?
| | Ducks | 1 | 1968 | 1 | 0.010 |
Why?
| | Chromatography | 1 | 1968 | 6 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 1968 | 16 | 0.010 |
Why?
| | Trypsin Inhibitors | 1 | 1968 | 2 | 0.010 |
Why?
| | Goats | 1 | 1968 | 11 | 0.010 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1968 | 10 | 0.010 |
Why?
| | Hot Temperature | 1 | 1968 | 26 | 0.010 |
Why?
| | Guinea Pigs | 1 | 1968 | 69 | 0.010 |
Why?
| | Cricetinae | 1 | 1968 | 48 | 0.010 |
Why?
| | Horses | 1 | 1968 | 29 | 0.010 |
Why?
| | Swine | 1 | 1968 | 101 | 0.010 |
Why?
| | Chickens | 1 | 1968 | 53 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1968 | 166 | 0.010 |
Why?
| | Cattle | 1 | 1968 | 254 | 0.010 |
Why?
| | Rabbits | 1 | 1968 | 317 | 0.010 |
Why?
|
|
Levine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|